AndrewPoklepovicMD

Breast Cancer, Gastrointestinal Cancer, Melanoma, Sarcoma

Assistant Professor, Internal Medicine, Virginia Commonwealth University, Medical College of Virginia School of Medicine

Join to view full profile

Dr. Poklepovic is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Poklepovic's full profile

Already have an account?

Office
VCU Massey Cancer Center1201 East Marshall Street, PO Box 980070
McGlothlin Medical education Center 11th floor,
Richmond, VA 23298
Phone+1 804-828-7999

Fax+1 804-828-5941
Is this information wrong?

Education & Training

Virginia Commonwealth University Health SystemFellowship, Hematology and Medical Oncology, 2008 - 2011
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2004 - 2007
University of South Florida College of MedicineClass of 2004

Certifications & Licensure

VA State Medical License 2004 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Start of enrollment: 2004 Sep 01
Completed
Phase 1
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
Completed
Phase 2
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer Start of enrollment: 2010 Aug 10
Completed
Phase 1
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14
Completed
Phase 1
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers Start of enrollment: 2011 Aug 11
Completed
Phase 1
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease Start of enrollment: 2011 Sep 01
Terminated
Early Phase 1
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Start of enrollment: 2011 Sep 01
Completed
Phase 3
Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors Start of enrollment: 2011 Oct 01
Completed
Phase 1
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Start of enrollment: 2013 Feb 01
Completed
Phase 2
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Start of enrollment: 2013 Oct 02
Completed
Phase 2
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab Start of enrollment: 2014 May 05
Completed
Phase 1
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer Start of enrollment: 2016 Jan 28
Terminated
Phase 2
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer Start of enrollment: 2016 Jul 08
Terminated
Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca Start of enrollment: 2019 May 01
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors.
Andrew S Poklepovic, Sarah W Gordon, Sejal Kothadia, William P McGuire, Leroy R Thacker, Xiaoyan Deng, Mary Beth Tombes, Ellen Shrader, Daniel Hudson, Dipankar Bandyop...> ;Anti-Cancer Drugs. 2024 Jun 1
US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma.
Rachel A Fischer, Isabel Ryan, Kristine De La Torre, Cody Barnett, Viren S Sehgal, Joan B Levy, Jason J Luke, Andrew S Poklepovic, Marc S Hurlbert> ;Critical Reviews in Oncology/hematology. 2024 Apr 1
Delayed Postoperative Intracerebral Hemorrhage Associated With Oral Multikinase Inhibitor Therapy for Cancer: A Case Report.
Asha Krishnakumar, Edward H Yang, Vishal C Patel, Andrew S Poklepovic, William C Broaddus> ;Cureus. 2024 Feb 1
Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells.
Laurence Booth, Jane L Roberts, Andrew Poklepovic, Paul Dent> ;Anti-Cancer Drugs. 2024 Feb 1
1 citations
Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells.
Laurence Booth, Andrew Poklepovic, John F Hancock, Paul Dent> ;Anti-Cancer Drugs. 2023 Oct 1
Granulomatous Cardiomyopathy Presenting As a Paraneoplastic Syndrome in Metastatic Melanoma.
Jeffrey Kolominsky, Andrew Poklepovic, Aamer Syed, Valentina Robila, Krishnasree Rao, Inna Tchoukina, Kenneth A Ellenbogen, Antonio Abbate, Wendy Bottinor, Jordana Kron> ;CJC Open. 2023 Sep 1
Tumor cell p38 inhibition to overcome immunotherapy resistance.
Jason J Luke, Rebekah E Dadey, Ryan C Augustin, Sarah Newman, Krishna B Singh, Rose Doerfler, Sarah Behr, Patrice Lee, Brian Isett, Christopher Deitrick, Aofei Li, Mar...> ;Research Square. 2023 Aug 19
2 citations
Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma.
Hannah M Lee, Matthew Nguyen, Sean C Dougherty, Yuesheng Qu, Leroy R Thacker, Andrew Poklepovic, Alder, L., Laura Alder> ;Journal of Gastrointestinal Oncology. 2023 Jun 30
1 citations
Immune Checkpoint Inhibitor Rechallenge in a Patient With Previous Fulminant Myocarditis.
Sherin M Menachery, Yiwei Hang, Laura Pritchard, Andrew Poklepovic, Wendy Bottinor> ;The American Journal of Cardiology. 2023 Jul 15
123 citations
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost, John R Hyngstrom, Siwen Hu-Lieskovan, Christopher D Lao, Leslie A Fecher, Thach-Giao Truon...> ;The New England Journal of Medicine. 2023 Mar 2
Multiple Immunotherapy-Related Cardiovascular Sequelae.
Sherin M Menachery, David Chuquin, Ariel Sindel, Andrew Poklepovic, Antonio Abbate, Wendy Bottinor> ;CJC Open. 2023 Feb 1
1 citations
AR12 increases BAG3 expression which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy.
Paul Dent, Laurence Booth, Jane L Roberts, Andrew Poklepovic, Jennifer Martinez, Derek Cridebring, Eric M Reiman> ;Aging. 2022 Oct 13
4 citations
BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours.
Pashtoon Murtaza Kasi, Sakti Chakrabarti, Sarah Sawyer, Michael Krainock, Andrew Poklepovic, George Ansstas, Minu Maninder, Meenakshi Malhotra, Joe Ensor, Ling Gao, Ze...> ;BMJ Open. 2022 May 30
165 citations
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Jason J Luke, Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, Muhammad A Khattak, Dirk Schadendo...> ;Lancet. 2022 Apr 30
The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant.
Stacey A Cohen, Anup Kasi, Nicole Hook, Michael Krainock, Griffin Budde, Allyson Koyen Malashevich, Jeffrey Meltzer, Russ Jelsema, Perry Olshan, Paul R Billings, Alexe...> ;Case Reports in Obstetrics and Gynecology. 2022 Jan 1
34 citations
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.
Mark Yarchoan, Leslie Cope, Amanda N Ruggieri, Robert A Anders, Anne M Noonan, Laura W Goff, Lipika Goyal, Jill Lacy, Daneng Li, Anuj K Patel, Aiwu R He, Ghassan K Abo...> ;The Journal of Clinical Investigation. 2021 Dec 15
1 citations
Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling
Paul Dent, Laurence Booth, Andrew Poklepovic, John M. Kirkwood> ;Pigment Cell & Melanoma Research. 2021 Sep 4
1 citations
The development of multi-kinase inhibitors as pancreatic cancer therapeutics.
Paul Dent, Andrew Poklepovic, Laurence Booth, John F. Hancock> ;Anti-Cancer Drugs. 2021 Sep 1
7 citations
Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43
Paul Dent, Laurence Booth, Jane L. Roberts, Andrew Poklepovic, Derek Cridebring, Eric M. Reiman> ;Aging. 2021 Jul 12
11 citations
Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib.
Paul Dent, Laurence Booth, Andrew Poklepovic, Daniel D. Von Hoff, Jennifer Martinez, Yong Zhou, John F. Hancock> ;Biochemical Pharmacology. 2021 May 30
75 citations
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Daniel J Olson, Zeynep Eroglu, Bruce Brockstein, Andrew Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, Mario R. Velasco, Jose Lutzky, Emily F. Higgs, Riyue B...> ;Journal of Clinical Oncology. 2021 May 4
2 citations
Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells.
Jane L Roberts, Laurence Booth, Andrew Poklepovic, Paul Dent> ;Frontiers in Oncology. 2021 Jan 1
8 citations
Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity.
Xiaofei Yu, Wenjie Liu, Shixian Chen, Xueqian Cheng, Patrick A Paez, Tuan-Wei Sun, Fang Yuan, Chunyan Wei, Joseph W. Landry, Andrew Poklepovic, Harry D. Bear, John R. ...> ;Journal for Immunotherapy of Cancer. 2021 Jan 1
19 citations
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.
Veronica Mariotti, Hyo S. Han, Roohi Ismail-Khan, Shou-Ching Tang, Patrick M. Dillon, Alberto J. Montero, Andrew Poklepovic, Susan A. Melin, Nuhad K. Ibrahim, Eugene P...> ;JAMA Oncology. 2021 Jan 1
34 citations
AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication.
Jonathan O. Rayner, Rosemary A. Roberts, Jin Kim, Andrew Poklepovic, Jane L. Roberts, Laurence Booth, Paul Dent> ;Biochemical Pharmacology. 2020 Dec 1
Join now to see all

Press Mentions

Join GRAIL’s Unveiling of RTP Cancer Test Manufacturing SiteApril 21st, 2021
Massey Cancer Center Demonstrates Investigational Drug AR-12 Kills SARS-COV-2September 24th, 2020
Breakthrough! This Cancer Drug Can Help in COVID-19 Treatment; Read DetailsSeptember 23rd, 2020
Join now to see all

Hospital Affiliations

VCU Medical CenterRichmond, Virginia